U.S. Biologics Market Size & Outlook, 2024-2030
U.S. biologics market, 2018-2030 (US$M)
Related Markets
U.S. biologics market highlights
- The U.S. biologics market generated a revenue of USD 192,408.6 million in 2024 and is expected to reach USD 300,858.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.7% from 2025 to 2030.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating product in 2024.
- Antisense & RNAi Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2024 | USD 192,408.6 million |
| Market revenue in 2030 | USD 300,858.9 million |
| Growth rate | 7.7% (CAGR from 2025 to 2030) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Antisense & RNAi Therapeutics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal antibodies (MABs), Vaccines, Recombinant Proteins, Antisense & RNAi Therapeutics |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, U.S. accounted for 48.1% of the global biologics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. biologics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 41,805.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics market will help companies and investors design strategic landscapes.
Monoclonal antibodies (mabs) was the largest segment with a revenue share of 69.01% in 2024. Horizon Databook has segmented the U.S. biologics market based on monoclonal antibodies (mabs), vaccines, recombinant proteins, antisense & rnai therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S market for biologics accounted for the significant share in 2017 owing to rising R&D spending for biologic development coupled with the presence of a large number of FDA-approved drugs in the country.
The U.S. is hosting a large number of biologics pipelines in various stages of development. More than 900 biological molecules are under clinical investigation in the country. Steady growth in the number of new biological approvals in the country is anticipated to boost revenue generation for the U.S. market of biologics.
In 2015, 13 new therapeutic biologics were approved. In 2014, 10 top-selling biologics of U.S.-based companies such as Amgen and Biogen accounted for USD 73 billion with respect to revenue generation. Moreover, AbbVie’s HUMIRA is estimated to generate the highest revenue with USD 12.5 billion in sales.
Reasons to subscribe to U.S. biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. biologics market databook
-
Our clientele includes a mix of biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biologics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. biologics market size, by product, 2018-2030 (US$M)
U.S. Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
